AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Celldex Therapeutics Inc (NASDAQ:CLDX)
29.77 USD
+0.870 3.010%Sponsored Reports
Loading...
| Previous Close (in USD) | 28.9 |
|---|---|
| Change | +0.870 3.010% |
| 52 W H/L (in USD) | 35.790/17.850 |
| EBITDA (in USD) | -283.987M |
| PE Ratio | -- |
| Volume | 876113 |
| Diluted Eps TTM | -3.88 |
| Total Assets (in USD) | 582.983M |
|---|---|
| Total Liabilities (in USD) | 55.818M |
| Revenue TTM (in USD) | 1.545M |
| Cash (in USD) | 28.871M |
| Market Cap (in USD) | 2,687.361 M |
| Revenue Per Share TTM | 0.023 |
| Gross Profit TTM (in USD) | -243.529M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. Celldex Therapeutics, Inc. is headquartered in Hampton, New Jersey.
Employees: 198
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Anthony S. Marucci M.B.A. | Founder, Pres, CEO & Director | 1962 |
| 2. | Dr. Tibor Keler | Founder, Chief Scientific Officer & Exec. VP | 1959 |
| 3. | Mr. Sam Martin | Sr. VP, CFO, Sec. & Treasurer | 1971 |
| 4. | Mr. Freddy A. Jimenez Esq. | Sr. VP & Gen. Counsel | 1969 |
| 5. | Dr. Diane C. Young M.D. | Sr. VP & Chief Medical Officer | 1957 |
| 6. | Prof. Joseph P. Schlessinger Ph.D. | Co-Founder & Member of Scientific Advisory Board | 1945 |
| 7. | Ms. Sarah Cavanaugh | Sr. VP of Corp. Affairs & Admin. | 1975 |
| 8. | Patrick Till | Sr. Director of Investor Relations & Corp. Communications | NA |
| 9. | Dr. Ronald A. Pepin | Chief Bus. Officer & Sr. VP | 1956 |
| 10. | Ms. Elizabeth Crowley | Chief Product Devel. Officer & Sr. VP | 1972 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Income Before Tax | -258.8M | -157.863M | -141.429M | -112.325M | -70.738M |
| Minority Interest | - | - | - | - | - |
| Net Income | -258.8M | -157.863M | -141.429M | -122.783M | -70.511M |
| Selling General Administrative | 43.8M | 38.548M | 30.914M | 27.195M | 20.488M |
| Gross Profit | 1.5M | -156.53M | -111.128M | 2.357M | 4.651M |
| Reconciled Depreciation | 3.38M | 3.177M | 2.922M | 2.896M | 3.068M |
| Ebit | -258.8M | -195.078M | -142.042M | -115.234M | -71.243M |
| Ebitda | -255.42M | -191.901M | -139.034M | -101.867M | -67.558M |
| Depreciation And Amortization | 3.38M | 3.177M | 3.008M | 13.367M | 3.685M |
| Operating Income | -287.4M | -195.078M | -154.542M | -115.234M | -71.243M |
| Other Operating Expenses | 288.9M | 202.098M | 161.425M | 109.453M | 73.799M |
| Interest Expense | - | - | - | -2.909M | 0.112M |
| Tax Provision | - | - | 0M | 0M | -0.227M |
| Interest Income | - | - | - | - | - |
| Net Interest Income | - | - | - | - | - |
| Income Tax Expense | - | -157.863M | 2.84M | 10.458M | -0.227M |
| Total Revenue | 1.5M | 7.02M | 6.883M | 2.357M | 4.651M |
| Total Operating Expenses | 288.9M | 38.548M | 43.414M | 109.453M | 73.799M |
| Cost Of Revenue | - | 163.55M | 118.011M | - | - |
| Total Other Income Expense Net | 28.6M | 37.215M | 13.113M | 2.909M | 0.505M |
| Net Income From Continuing Ops | -258.757M | -157.863M | -124.61M | -112.325M | -70.511M |
| Net Income Applicable To Common Shares | - | - | - | -112.325M | -70.511M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Total Assets | 582.983M | 792.34M | 465.627M | 352.735M | 444.654M |
| Intangible Assets | 27.19M | 27.19M | 27.19M | 31.295M | 30.264M |
| Other Current Assets | 14.076M | 21.178M | 5.467M | 12.741M | 2.589M |
| Total Liab | 55.818M | 45.335M | 36.456M | 26.531M | 25.178M |
| Total Stockholder Equity | 527.165M | 747.005M | 429.171M | 326.204M | 419.476M |
| Other Current Liab | 48.259M | 34.784M | 26.017M | 13.825M | 1.554M |
| Common Stock | 0.067M | 0.066M | 0.056M | 0.047M | 0.047M |
| Capital Stock | 0.067M | 0.066M | 0.056M | 0.047M | 0.047M |
| Retained Earnings | -1813.981M | -1555.224M | -1397.361M | -1255.932M | -1143.607M |
| Good Will | - | - | - | - | - |
| Other Assets | - | - | - | 0.104M | 0.104M |
| Cash | 28.871M | 28.356M | 34.814M | 29.429M | 39.143M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 50.991M | 39.501M | 31.125M | 18.61M | 16.528M |
| Current Deferred Revenue | - | - | - | - | 12M |
| Net Debt | -26.535M | -24.543M | -32.272M | -25.396M | -36.101M |
| Short Term Debt | 1.552M | 1.452M | 1.614M | 1.445M | 1.746M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 2.336M | 3.813M | 2.542M | 4.033M | 3.042M |
| Other Stockholder Equity | 2337.453M | 2298.849M | 1823.168M | 1580.829M | 1561.142M |
| Property Plant Equipment | - | - | - | 7.748M | 6.521M |
| Total Current Assets | 534.664M | 747.159M | 431.693M | 317.693M | 410.839M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 489.702M | 696.925M | 386.884M | 275.523M | 369.107M |
| Net Receivables | 2.015M | 0.7M | 4.528M | 0.347M | 0.172M |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | 0M | -0.347M | -0.172M |
| Accounts Payable | 1.18M | 3.265M | 3.494M | 3.34M | 1.228M |
| Accumulated Other Comprehensive Income | 3.626M | 3.314M | 3.308M | 1.26M | 1.894M |
| Non Currrent Assets Other | 13.358M | 9.747M | 0.107M | 0.104M | 0.104M |
| Non Current Assets Total | 48.319M | 45.181M | 33.934M | 35.042M | 33.815M |
| Capital Lease Obligations | 2.336M | 3.813M | 2.542M | 4.033M | 3.042M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2025 | 31-12-2024 | 31-12-2023 | 31-12-2022 | 31-12-2021 |
|---|---|---|---|---|---|
| Investments | 211.786M | -290.129M | -105.782M | 89.942M | -214.934M |
| Total Cashflows From Investing Activities | 209.072M | -290.129M | - | 89.942M | -216.156M |
| Total Cash From Financing Activities | 2.388M | 441.449M | 218.458M | 4.076M | 272.372M |
| Net Income | -258.757M | -157.863M | -141.429M | -112.325M | -70.511M |
| Change In Cash | 0.515M | -6.458M | 5.385M | -9.714M | -4.693M |
| Begin Period Cash Flow | 28.356M | 34.814M | 29.429M | 39.143M | 43.836M |
| End Period Cash Flow | 28.871M | 28.356M | 34.814M | 29.429M | 39.143M |
| Total Cash From Operating Activities | -210.945M | -157.778M | -107.291M | -103.732M | -60.909M |
| Depreciation | -2.475M | 3.177M | 3.008M | 2.896M | 3.068M |
| Other Cashflows From Investing Activities | -2.714M | -1.919M | - | - | 0.027M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | - | - | 272.372M |
| Other Cashflows From Financing Activities | 2.388M | 9.151M | 2.236M | 4.076M | 2.479M |
| Capital Expenditures | 2.714M | 1.919M | 1.818M | 1.828M | 1.249M |
| Change In Working Capital | 14.058M | -21.601M | 13.462M | -3.898M | -1.054M |
| Other Non Cash Items | 0.012M | -15.733M | -6.222M | -5.789M | -1.138M |
| Free Cash Flow | -213.659M | -159.697M | -109.109M | -105.56M | -62.158M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Health Care Inv | 5 months ago | 4249656 |
| 2. | BB Biotech AG Ord | 8 months ago | 3557669 |
| 3. | Vanguard Total Stock Mkt Idx Inv | 2 months ago | 2148156 |
| 4. | Vanguard Institutional Extnd Mkt Idx Tr | 2 months ago | 744079 |
| 5. | Fidelity Small Cap Index | 4 months ago | 633144 |
| 6. | Pictet-Biotech P USD | 5 months ago | 620141 |
| 7. | Eventide Gilead N | 5 months ago | 599317 |
| 8. | iShares Russell 2000 Value ETF | 2 months ago | 560991 |
| 9. | American Century U.S. Small Cap Growth | 2 months ago | 548022 |
| 10. | iShares Russell 2000 ETF | 2 months ago | 1588482 |
| 11. | State Street® SPDR® S&P® Biotech ETF | 2 months ago | 1279288 |
| 12. | Vanguard Explorer Inv | 5 months ago | 1057540 |
| 13. | Eventide Healthcare & Life Sciences I | 5 months ago | 1037000 |
| 14. | American Century Small Cap Growth Inv | 2 months ago | 548022 |
| 15. | US Small-Cap Growth II Equity Comp | 5 months ago | 538361 |
| 16. | T. Rowe Price New Horizons | 2 months ago | 533194 |
| 17. | FIAM Small Cap Core Composite | 5 months ago | 532900 |
| 18. | FIAM Small Cap Core CIT Cl B | 4 months ago | 532900 |
| 19. | Strategic Advisers Fidelity US TtlStk | 3 months ago | 531499 |
| 20. | Fidelity Small Cap Growth | 4 months ago | 473857 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Wellington Management Company LLP | 5 months ago | 8079608 |
| 2. | Deep Track Capital, LP | 5 months ago | 1900738 |
| 3. | BRAIDWELL LP | 5 months ago | 1858109 |
| 4. | Point72 Asset Management, L.P. | 5 months ago | 1758357 |
| 5. | Eventide Asset Management, LLC | 5 months ago | 1642559 |
| 6. | Geode Capital Management, LLC | 5 months ago | 1627529 |
| 7. | Eversept Partners, LP | 5 months ago | 1434725 |
| 8. | Millennium Management LLC | 5 months ago | 1212705 |
| 9. | Novo A/S | 5 months ago | 1200000 |
| 10. | Vestal Point Capital LP | 5 months ago | 1165000 |
| 11. | The Goldman Sachs Group Inc | 5 months ago | 1068131 |
| 12. | Polar Capital Holdings PLC | 5 months ago | 1008163 |
| 13. | Kynam Capital Management, LP | 5 months ago | 5943180 |
| 14. | BlackRock Inc | 8 months ago | 5505988 |
| 15. | FMR Inc | 5 months ago | 4907469 |
| 16. | Vanguard Group Inc | 5 months ago | 4027407 |
| 17. | Bellevue Group AG | 5 months ago | 3617669 |
| 18. | State Street Corp | 8 months ago | 2842134 |
| 19. | COMMODORE CAPITAL LP | 5 months ago | 2565000 |
| 20. | T. Rowe Price Associates, Inc. | 8 months ago | 2382518 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...